



Changing the course of cancer treatment



Q2

Report on the second quarter 2023

# Significant events of Q2 2023

- » Net sales for the period amounted to KSEK - (-)
- » Result for the period amounted to KSEK -27,737 (-29,318).
- » Earnings and diluted earnings per share totaled SEK -0.02 (-0.15)
- » Mendus held an investor update call following the Annual Report publication on April 17, 2023
- » Mendus receives ATMP certificate from European Medicines Agency supporting its lead pipeline program vididencel
- » Mendus presents comprehensive ADVANCE II immuno-monitoring data at the EHA Annual Meeting 2023
- » Mendus presented updated clinical data from ADVANCE II trial in an oral presentation and a scientific poster on a next-generation immune primer program at the 2023 CIMT Annual Meeting
- » Mendus presented positive data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023
- » Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board
- » Mendus reports outcome from the Annual General Meeting on May 12, 2023
- » Mendus redeemed the outstanding convertible bonds from Negma Group
- » Mendus secures third shareholder loan from Van Herk Investments
- » Mendus announces a directed share issue and a fully secured rights issue of units totaling approximately SEK 317 million in financing
- » Mendus and NorthX Biologics to enter into strategic cell therapy manufacturing alliance supported by new investor Flerie
- » Mendus' provides update and outlook on vididencel program in online and on-site events on June 27, 2023

## Significant events after end of reporting period

- » Mendus reports outcome from the Extraordinary General Meeting on July 10, 2023
- » Mendus publishes prospectus regarding previously announced rights issue and directed issue
- » Mendus reports outcome of previously announced rights issue and directed issue

## Financial summary

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Net sales	-	-	-	-	-
Operating profit/loss	-27,737	-28,133	-57,346	-54,953	-133,957
Net profit/loss	-3,886	-29,318	-34,054	-56,900	-138,786
Earnings/loss per share, before and after dilution (SEK)	-0.02	-0.15	-0.17	-0.29	-0.70
Cash	20,186	84,855	20,186	84,855	41,850
Shareholders equity	485,171	600,339	485,171	600,339	514,439
Average number of employees	30	32	30	32	31



### In the second quarter of 2023, Mendus' main objectives were focused on driving the evolution of our pipeline and securing the related financing.

The progress made in the previous quarters, including the positive survival data of the ADVANCE II trial, improvements of our production processes and adjusting our strategy to the rapidly evolving cancer therapy landscape, provided the basis for a next financing round, which we announced last June. The directed placement and rights issue totaling approximately SEK 317M will support the ongoing ADVANCE II and ALISON vididencel trials, the start of a combination trial with vididencel in AML maintenance and the start of a new clinical trial with ilixadencel in soft tissue sarcomas. The new financing will furthermore be used for the development of our preclinical NK cell program and the recently announced manufacturing alliance with NorthX Biologics.

Mendus is committed to changing the course of cancer treatment by positioning our product candidates where they can have the biggest impact on survival, combined with a benign safety profile. This is particularly relevant for cancer maintenance therapy, which aims to extend disease-free survival following initial treatment. Our lead program vididencel is currently studied in the ADVANCE II monotherapy Phase 2 trial as a maintenance therapy for acute myeloid leukemia (AML). Following the positive survival data reported at the end of 2022, we prepare for a next read-out of the ADVANCE II trial in the fourth quarter of 2023. In the meantime, we carry out the in-depth analysis of the study samples collected as part of the trial. These immunomonitoring data provide useful insights in the interaction between vididencel and the immune system. Immunological analyses of



Erik Manting, Chief Executive Officer.

patient samples before and after vididencel treatment support vididencel's mode of action as an immunotherapy, which boosts antitumor responses against residual disease, and were presented at the CIMT and EHA conferences during the second quarter.

Based on the monotherapy efficacy data and excellent safety profile reported in the ADVANCE II trial, combined with supportive preclinical data, an obvious next step is to combine vididencel with oral azacitidine, currently the only approved drug for AML maintenance. This new combination trial is expected to start before the year-end of 2023. The trial with oral azacitidine will be important to study this combination in the clinical setting and as a step-up towards pivotal-stage development. In parallel, Mendus will set up the large-scale manufacturing of vididencel required for late-stage clinical development and commercial-

ization. For this, Mendus has closed a manufacturing alliance with NorthX Biologics, a leading Swedish contract development and manufacturing organization for cell and gene therapies. This alliance will provide stability for our manufacturing plans and bring additional resources and competence. NorthX Biologics will be a significant partner going forward.

Initial data from the Phase 1 ALISON trial studying vididencel as a maintenance therapy in ovarian cancer were presented at the American Association for Cancer Research (AACR) conference held in April 2023. The data confirmed the benign safety profile and potential of vididencel to stimulate immune responses against tumor antigens previously shown to be relevant for ovarian cancer. Based on the positive data, recruitment of the ALISON trial will continue and additional read-outs of the trial are expected in the coming months.

Following a series of manufacturing process improvements, Mendus' second clinical-stage program ilixadencel is ready to be tested in a proof-of-concept trial based on initial positive data observed in gastrointestinal stromal tumors (GIST). There continues to be clinical interest in pursuing a trial in soft-tissue sarcomas, of which GIST is a subtype. We will choose the exact indication based on medical need and competition from other drugs in development and expect a next trial to commence before year-end 2023.

Mendus has earmarked the application of its proprietary DCOne platform to expand natural killer (NK) cells for therapeutic purposes as the main



focus of its preclinical research activities. We particularly focus on memory NK cells, which are associated with improved persistence, metabolic fitness and tumor cell killing capacity and reduced relapse rates in blood-borne tumors. We were happy to announce during the second quarter the appointment of NK cell pioneer Lewis Lanier to our Scientific Advisory Board.

Concluding, the first half of 2023 has provided the basis for the next phase of corporate development for Mendus.

With two programs moving forward in the clinic on a solid basis and a promising preclinical pipeline, the Company is positioned stronger than ever before to address key challenges in today's cancer treatment.

Thank you for your continued support,

**Erik Manting, Ph.D.**  
Chief Executive Officer

# Mendus in Short – Q2 2023

Mendus is developing novel cancer therapies based on harnessing the power of the immune system. Our products aim to achieve durable clinical responses without harming health or quality of life.



Cancer treatment without harming health or quality of life.

The Company leverages its expertise in allogeneic dendritic cell biology to design off-the-shelf immunotherapies which enhance antitumor immunity. In clinical trials, our product candidates have shown promising signs of clinical efficacy in blood-borne and solid tumors, combined with an excellent safety profile. This is particularly relevant for maintenance therapies, aimed at the prevention or delay of tumor recurrence.

## **Changing the course of cancer treatment**

In today's cancer therapy landscape, many cancer patients experience an initial treatment success, leading to clinical remission. However, tumor

recurrence remains an imminent threat in many cases and causes the vast majority of cancer-related deaths today. As a result, there is an increasing need for maintenance therapies, particularly in tumor indications with a high recurrence rate. Maintenance therapies focus on controlling residual disease and prolonging relapse-free and overall survival, while keeping the patient's quality of life front and center.

## **Vididencel – positioned as a novel maintenance therapy in AML and ovarian cancer**

Vididencel is a cancer vaccine derived from the Company's proprietary DCOne cell line, which is currently being evaluated in clinical trials in acute

myeloid leukemia (AML) and ovarian cancer as a maintenance therapy to improve disease-free and overall survival.

Promising clinical data with vididencel were presented at various high-profile medical conferences. The results consistently demonstrated vididencel's ability to induce durable immune responses, combined with an excellent safety profile.

The ongoing ADVANCE II Phase 2 monotherapy trial evaluates single-agent activity of vididencel as maintenance therapy in AML, for patients brought into complete remission through chemotherapy, but with measurable residual disease (MRD).



The presence of MRD puts patients at a high risk of relapse and correlates with reduced overall survival.

Mendus presented positive survival data from the ADVANCE II trial in December 2022 at the ASH conference. The data showed that after completion of the active 70-week study period from start of vaccination, the majority of patients (14/20) were still alive. In the ongoing long-term follow-up phase of the trial, 12 patients remained disease-free in a period ranging from 16 to 47 months. At the time of the data cut, median follow-up was 19.4 months and median relapse-free survival was not yet reached, while the overall survival median stood at 30.9 months. Immunomonitoring data showed broadly increased immune responses against tumor-associated antigens following vididencel administration. Patients that had experienced a reduction in their MRD levels or a full conversion to the MRD- status also showed a higher number of immune responses, supporting vididencel's mode of action as an immune primer, which boosts anti-tumor immunity and improves immune control over residual cancer cells. Mendus expects to report a next survival read-out of the ADVANCE II trial in the second half of 2023.

The ADVANCE II monotherapy proof-of-concept data support the broader positioning of vididencel as a new treatment modality in AML maintenance. As a first step-up to pivotal-stage development, vididencel will be combined in a next clinical trial with oral azacitidine, the only approved maintenance therapy for transplant-ineligible AML patients.

Like AML, ovarian cancer is characterized by fast tumor recurrence following initial treatment, providing for the rationale to develop maintenance therapy options in this disease. Supported by preclinical data demonstrating vididencel's potential to stimulate anti-tumor immunity in ovarian cancer, the currently active and recruiting ALISON Phase 1 clinical trial explores safety and feasibility of vididencel as



a maintenance treatment in ovarian cancer. Interim data from the ALISON trial presented at AACR in Q2 2023 confirmed vididencel's excellent safety profile and demonstrated improved immune responses against tumor antigens previously shown to be relevant for ovarian cancer following vididencel administration. Mendus expects to report additional updates from the ALISON trial in the second half of 2023.

In parallel to the continued clinical development of vididencel, Mendus will implement a large-scale manufacturing process and expand the manufacturing infrastructure. In Q2 2023, Mendus initiated a strategic manufacturing alliance with NorthX Biologics, a leading Contract Development and Manufacturing Organization (CDMO) in the Nordics, which also serves as the National Swedish Innovation Hub for the GMP manufacture of biologics used in vaccines, gene therapy and other advanced therapy medicinal products (ATMPs). Mendus and

NorthX will co-establish cell therapy manufacturing capabilities in Sweden, which will be used for late-stage clinical development and commercial manufacturing of vididencel.

### **Ilixadencel – an intratumoral immune primer for hard-to-treat solid tumors**

Ilixadencel is Mendus' most advanced intratumoral immune primer candidate in development. Intratumoral immune primers are injected into the tumor of a patient to produce an inflammatory environment and ultimately a tumor-specific immune response. Ilixadencel consists of allogeneic proinflammatory dendritic cells derived from healthy donor material.

Ilixadencel has been studied in clinical trials across a range of solid tumor indications in combination with existing cancer therapies, including tyrosine kinase inhibitors and the immune checkpoint inhibitor pembrolizum-

ab. Preclinical results furthermore suggest synergies between intratumoral priming and CTLA-4 inhibitors, another class of checkpoint inhibitor. Overall, a substantial body of pre-clinical and clinical data underscore ilixadencel's potential as a safe and feasible combination therapy in cancer therapy.

Mendus has prepared for next clinical development steps with ilixadencel to establish proof-of-concept in tumors that are poorly responding to current available therapies. Based on initial signs of clinical efficacy in gastro-intestinal stromal tumors (GIST), Men-


us aims to confirm clinical efficacy of ilixadencel in soft tissue sarcomas, of which GIST is a subclass, in a next clinical trial.

### Preclinical pipeline

In addition to supporting the clinical development and manufacturing processes of the Company's lead programs, Mendus' research activities include the design of next-generation immune primers based on the DCOne cell line as well as leveraging internal pipeline synergies through the combination of vaccination and intratumoral priming.

Mendus has also applied its expertise in dendritic cell biology to improve other cell-based therapies. Particularly, Mendus has explored the application of the proprietary DCOne platform to expand memory NK cells, an important subset of NK cells because of their longevity, resistance to immune suppression and correlation with improved clinical outcomes in blood-borne tumors. Establishing a novel method to expand this class of NK cells may provide the basis for novel, improved NK cell-based therapies, as a potential new program in the Mendus pipeline.

## Advanced clinical pipeline with near-term value inflection potential



# Strengthening Mendus' manufacturing capabilities creates value

Interview with **Leopold Berte**a, Chief Technology Officer, at Mendus, and **Thomas Beck**, Vice President Quality, at NorthX Biologics

As Mendus' product pipeline advances towards later-stage clinical development and subsequently commercialization, the company has taken the necessary steps to build a global manufacturing infrastructure and bolster the process development for its current and future products. Among these efforts, the most recent announcement with NorthX Biologics, a leading contract development and manufacturing organization (CDMO) in the Nordics, represents the start of a strategic alliance to achieve these goals.

Mendus' Chief Technology Officer (CTO) Leopold Berte and Thomas Beck, Vice President Quality at NorthX Biologics share their views on the current status and next steps in the collaboration.

**From your perspective, what are the specific challenges when producing cell-based therapies such as Mendus' product candidate vididence<sup>1</sup> at a larger scale?**

**TB:** In contrast to chemically derived drugs and even in contrast to other biologics such as monoclonal antibodies, developing and manufacturing cell therapies brings a much greater deal of complexity. A "living drug" composed of cells must be kept alive and active until it is delivered to the patient.

We, as a manufacturer, together with the drug developers we partner with, need to ensure that all steps from the starting cell material, the production process, the storage and shipping conditions are done under perfect control, reproducibly and according

to a robust end-to-end process.

Obviously despite all these challenges, such a "living drug" has many potential benefits. It is not composed of only one molecular entity, like a therapeutic protein for example, but





**“NorthX has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies. Mendus is a great fit with this ambition level, as they are entering an advanced stage of clinical development and are experts in dendritic cell biology, which translates to other immune cells.”**

*Thomas Beck, Vice President Quality, at NorthX Biologics*



should be rather considered something like a “biological factory” that can have multiple treatment mechanisms and effects. So, for the potential benefit of patients with unmet medical needs, it is well worth the effort to develop them.

**LB:** I totally agree. At Mendus, we aim to make smart choices concerning the development of manufacturing processes for such complex cellular products and thus balance our efforts between scaling up to achieve larger production volumes, so literally making everything that is in direct contact with the product bigger, or rather scaling out. Scaling out means we keep the same manufacturing process, volumes, and elements, but “simply” do this multiple times in parallel. With this modular approach, each unit of product is subject to exactly the same processing conditions. Multiplying the

same process units will increase the overall product output to match future patient needs and warrant a perfectly reproducible product quality.

I am convinced that Mendus is securing value early on by sorting out the way we approach large scale manufacturing now rather than later, providing a robust large-scale process able to meet upcoming clinical needs, and eventually scale it out to secure the future launch of our novel cell therapies.

**Can you both provide some color on the recently announced strategic manufacturing alliance between Mendus and NorthX?**

**LB:** The alliance with NorthX provides the opportunity to establish a dedicated facility and team to manufacture

videnced for the final stages of clinical development and, subsequently, commercialization. Visiting the team on-site ahead of the announcement showed that NorthX uniquely combines innovation in process development and the industrial know-how to scale up GMP manufacturing of advanced therapy medicinal products. So, being convinced of the capability of NorthX and the quality of their work was front and center in the decision to partner with them.

The fact that Flerie, an investor of NorthX, has decided to invest in Mendus, covering the initial phase of the alliance, was an added benefit. Last and not least, the commitment and support from the Swedish government to build up world-class manufacturing expertise in Mendus’ home country, represents a perfect win-win situation.

**TB:** Our team has been manufacturing biologics under GMP standards since 1992, but NorthX has the wider ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies worldwide, as well. And to achieve this goal, we are looking for lighthouse projects and committed partners that we can team up with and grow our business and expertise with them.

Mendus has done a great job, bringing an innovative cell-based cancer vaccine into mid-stage clinical development and publish promising data around it. They have also done their homework very well and ahead of time to prepare the large-scale manufacturing so we can come in and do our part well. And it is a product that if continued development confirms the clinical benefits and once it is produced in sufficient quality, quantity and at acceptable costs, could make a huge impact on the course of cancer treatment and change many patients' lives for the better. Hence, we are thrilled to be part of the journey.

### **How important is the off-the-shelf nature of Mendus' products from a medical and practical perspective?**

**LB:** We at Mendus and many others in medical research believe that allogeneic, or off-the-shelf therapies, will in the future contribute a large portion to oncology breakthroughs, in particular concerning the cell-based treatments. Both our current clinical programs are allogeneic. This has many advantages compared to the autologous approach mostly by avoiding a very complex and costly supply chain, and by providing the therapy "off-the-shelf", as soon as the patient needs it.

But it is also not a clear-cut thing. At the end of the day, frankly speaking, whatever serves patients best, is the way to go. We are not dogmatic about this either. As an example, besides working on allogeneic dendritic cell-based vaccines and novel immune primers, we have started a new initiative in manufacturing so-called memory NK cells with the help of our DCOne-based technology platform.

This activity may take us into both allogeneic and autologous applications in the future.

**TB:** As a CDMO, we are naturally looking at both ends of the spectrum to see how we can contribute value to the respective product supply chains and support our customers. Using vials from a cell line stored in the freezer as starting material or even using cells from a healthy donor to start a production is naturally a lot more convenient than having to timely obtain and process cells from a patient, ship them to another location for the modification and expansion steps, and deliver them back to the same patient in the hospital.

Going back one step, the fact that Mendus main product is based on the well characterized DCOne cell line and that the team has gathered a substantial amount of data and expertise on how to handle these cells and turn them into a product candidate is a great asset. As a manufacturing partner, that's a great starting point to have.



*NorthX Biologics facility in Matfors, Sweden.*

# Financial information

## The Group

### Revenue

No sales were reported for the second quarter (-) or for the first half of the year KSEK - (1,794). Other operating income amounted to KSEK 13 (35) for the quarter and KSEK 299 (152) for the first half of the year and consisted mainly of income for patent transfer.

### Operating expenses

Total operating expenses for the second quarter amounted to KSEK -27,750 (-28,169) and to KSEK -57,645 (-56,899) for the first half of the year. Operating expenses were related to administrative and research and development costs of the DCOne® platform and the programs of Vididencel and Ilixadencel.

### Research and development costs

Research and development costs for the second quarter amounted to KSEK -19,221 (-18,687) and KSEK -39,003 (-37,502) for the first half of the year. The costs consist primarily of activities relating to clinical studies. The increase for the period largely relates to costs for third parties related to development and manufacturing costs.

### Administrative expenses

Administration expenses for the second quarter amounted to KSEK -8,438 (-9,226) and for the first half-year KSEK -18,352 (-18,480). Included costs in administration (G&A) are mainly attributable to the finance department, Group management and costs associated with investment activities.

### Result

For the second quarter, the operating loss amounted to KSEK -27,737 (-28,133) and for the first half-year to KSEK -57,346 (-54,953). The result for the second quarter

amounted to KSEK -3,886 (-29,318) and for the first half of the year to KSEK -34,054 (-56,900). The improved result is due to the Company being granted a larger contribution.

Earnings per share before and after dilution for the Group amounted to SEK -0.02 (-0.15) for the second quarter and SEK -0.17 (-0.29) for the first half of the year.

### Tax

No tax was reported for the second quarter or for the first half of the year.

### Cash flow, investments and financial position

Cash flow from operating activities for the second quarter amounted to KSEK -7,313 (-38,106) and to KSEK -40,867 (-70,667) for the half-year. The enhanced cash flow is primarily a result of receiving a contribution.

During the quarter, cash flow from investing activities amounted to KSEK 2,815 (-3,633) and KSEK 2,320 (-11,290) for the half-year and relates to investments in equipment. Cash flow from financing activities for the second quarter amounted to KSEK -12,650 (1,572) and for the half-year KSEK 17,038 (-33) and relates to the raising of a new loan during the half-year, repayment of loans in the second quarter and a new share issue.

The company's cash and cash equivalents on June 30, 2023 amounted to KSEK 20,186 (84,855).

Total equity amounted to KSEK 485,171 (600,340) as of June 30, 2023, which corresponds to SEK 2.39 (3.01) per share. The company's equity/assets ratio at the end of the quarter was 81% (88%).



# Financial information

## Parent Company Mendus AB

### Revenue

No sales were reported for the second quarter (-) or for the first six months KSEK (1,794). Other operating income amounted to KSEK 660 (866) for the quarter and KSEK 1,808 (1,732) for the first half of the year and consisted mainly of re-invoiced costs to Mendus B.V and income for patent transfer.

### Operating expenses

Total operating expenses for the second quarter amounted to KSEK -10,593 (-15,678) and to KSEK -22,106 (-31,363) for the first half of the year. Operating expenses were related to administrative and research and development costs of the DCOne® platform and the programs of Vididencel and Ilixadencel. The lower costs in the second quarter, compared to last year, are primarily related to the repayment of upfront payments.

### Research and development costs

Research and development costs for the second quarter amounted to KSEK -7,085 (-5,125) and to KSEK -10,218 (-12,164) for the first half of the year. The costs consist primarily of activities relating to clinical studies. The increased costs in the second quarter are mainly due to higher intra-group costs compared with last year.

### Administrative expenses

Administration expenses for the second quarter amounted to KSEK -3,485 (-10,300) and for the first half-year KSEK -11,693 (-18,286). Included costs in administration (G&A) are mainly attributable to the finance department, Group management and costs associated with investment activities.

### Result

For the second quarter, the operating loss amounted to KSEK -9,933 (-14,812) and for the first half year to KSEK -20,298 (-27,837). The loss for the second quarter amounted to KSEK -11,013 (-14,795) and for the first half-year to KSEK -21,622 (-27,642). Earnings per share before and after dilution for the Parent Company amounted to SEK -0.06 (-0.07) for the second quarter and SEK -0.11 (-0.14) for the first half of the year.

### Tax

No tax was reported for the second quarter or half year.

### Cash flow, investments and financial position

Cash flow from operating activities for the second quarter amounted to KSEK 1,181 (-37,216) and to KSEK -9,920 (-71,746) KSEK for the half-year. The negative cash flow is according to plan and is mainly explained by the Company's research and development activities for the DCOne® platform and the programs for Vididencel and Ilixadencel.

During the quarter, cash flow from investing activities amounted to KSEK -30,448 (-21,155) and to KSEK -45,266 (-) for the half-year. Cash flow primarily refers to shareholder contributions to Mendus B.V.

Cash flow from financing activities for the second quarter amounted to KSEK 16,500 (-) and relates to raising new loans and new share issues.

The company's cash and cash equivalents on June 30, 2023 amounted to KSEK 18,667 (73,619).

Total equity amounted to KSEK 705,151 (759,351) as of June 30, 2023, which corresponds to SEK 3.48 (3.81) per share. The company's equity/assets ratio at the end of the quarter was 92% (96%).

# Other information

## Incentive program

The purpose of share-based incentive programs is to promote the company's long-term interests by motivating and rewarding the Company's senior management and other employees in line with the interests of the shareholders. There are currently two outstanding incentive programs in the Company.

### LTI 2021/2024

In accordance with a decision by the Annual General Meeting on May 4, 2021, it was resolved to introduce an incentive program with warrants and restricted shares; "LTI 2021/2024".

The number of subscribed employee warrants amounted to 1,286,092 and the number of subscribed share rights amounted to 680,000. In 2021, 40,000 restricted shares had been forfeited in connection with employees leaving. In 2022, 50,000 restricted shares and 50,000 warrants had been forfeited in connection with employees leaving. During the first half of 2023, 141,000 restricted shares and 79,167 warrants have been forfeited in connection with the termination of employees. Thus, the number of restricted shares issued amounts to 449,000 and issued warrants to 1,156,925, corresponding to a total of approximately 0.79 percent dilution upon full exercise.

### LTI 2022/2025

In accordance with a decision by the Annual General Meeting in May 2022, it was resolved to introduce an incentive program with warrants and restricted shares; "LTI 2022/2025".

The number of warrants subscribed for amounted to 3,000,000. During the first half of 2023, 169,167 warrants have been forfeited in connection with employees leaving. Thus, the number of warrants issued amounts to 2,830,833. This corresponds to a dilution of 1.4 percent if fully utilized.

For more information about the program, see minutes from the Annual General Meeting 2021 and 2022 published on the Company's website [www.mendus.com](http://www.mendus.com).

## Employees

As of June 30, 2023, the Group had 30 (34) employees, of whom 19 (21) women and 11 (13) men.

## Mendus share

The share is traded on Nasdaq Stockholm's main market under the ticker IMMU, with ISIN code SE0005003654. As of June 30, 2023, the number of shares in the Company amounted to 202,694,512 (199,400,599) and the share capital in the Company amounted to SEK 10,135 (9,970). All shares have equal voting rights and share of Mendus' assets and profits.

## Shareholders as of 2023-06-30

Source: Euroclear Sweden AB.

Owners	Shares	% of votes and capita
Adrianus Van Herk	85,397,754	42.1%
Fourth Swedish National Pension Fund	19,575,980	9.7%
Avanza Pension	9,125,604	4.5%
Holger Blomstrand Byggnads AB	2,975,386	1.5%
Martin Lindström	1,875,000	0.9%
Nordnet Pension Insurance	1,736,591	0.9%
Erik Manting	1,328,474	0.7%
Dharminder Chahal	1,323,073	0.7%
Swedbank Insurance	1,010,286	0.5%
Handelsbanken Funds	960,932	0.5%
Lennart Sten	875,000	0.4%
Ivar Nordqvist	830,256	0.4%
SEB Funds	814,249	0.4%
Bengt Andersson	671,319	0.3%
Mats Artur Andersson	625,000	0.3%
Alex Karlsson-Parra	621,736	0.3%
Mats Dahlgren	620,000	0.3%
Futur Pension	616,015	0.3%
Hans Edvin Ståhlgren	600,000	0.3%
Handelsbanken Liv Försäkring AB	587,052	0.3%
Other	70,524,805	34.5%

## Review

This report has not been reviewed by the Company's auditor.

FINANCIAL REPORTS  
**THE GROUP**



## Consolidated income statement

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Revenue	–	–	–	1 794	1 794
Other operating income	13	35	299	152	1 581
<b>Total revenue and other operating income</b>	<b>13</b>	<b>35</b>	<b>299</b>	<b>1 946</b>	<b>3 375</b>
<b>OPERATING EXPENSES</b>					
Administration expenses	-8,438	-9,226	-18,352	-18,480	-48,876
Research and development expenses	-19,221	-18,687	-39,003	-37,502	-87,049
Other operating expenses	-91	-256	-290	-917	-1,134
<b>Operating profit/loss</b>	<b>-27,737</b>	<b>-28,133</b>	<b>-57,346</b>	<b>-54,953</b>	<b>-133,684</b>
<b>RESULT FROM FINANCIAL ITEMS</b>					
Financial income	25,270	35	25,270	209	163
Financial costs	-1,419	-1,220	-1,979	-2,157	-5,264
<b>Profit/loss after financial items</b>	<b>-3,886</b>	<b>-29,318</b>	<b>-34,055</b>	<b>-56,900</b>	<b>-133,410</b>
<b>TOTAL PROFIT/LOSS BEFORE TAXES</b>	<b>-3,886</b>	<b>-29,318</b>	<b>-34,055</b>	<b>-56,900</b>	<b>-133,410</b>
Income tax	–	–	–	–	–
<b>PROFIT/LOSS FOR THE PERIOD</b>	<b>-3,886</b>	<b>-29,318</b>	<b>-34,055</b>	<b>-56,900</b>	<b>-133,410</b>
Earnings/loss per share before and after dilution (SEK), for profit attributable to owner of the parent company's shareholders.	-0.02	-0.15	-0.17	-0.29	-0.73

## Consolidated statement of comprehensive income

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
<b>Result for the period</b>	<b>-29,318</b>	<b>-3,886</b>	<b>-34,055</b>	<b>-56,900</b>	<b>-138,785</b>
<b>Other comprehensive income</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>–</b>
Exchange differences on translation of foreign operations	-8	-332	-154	-318	-3 819
<b>Other comprehensive income for the period</b>	<b>-8</b>	<b>-332</b>	<b>-154</b>	<b>-318</b>	<b>-3,819</b>
<b>Total comprehensive income for the period</b>	<b>-29,325</b>	<b>-4,218</b>	<b>-34,209</b>	<b>-57,219</b>	<b>-142,604</b>

Profit/loss for the period and total comprehensive income, are in their entirety attributable to the parent company's shareholders.

## Consolidated statement of financial position

Amounts in KSEK	2023-06-30	2022-06-30	2022-12-31
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Goodwill	108,350	108,350	108,350
Technology	424,091	424,091	424,091
Right-of-use assets	26,242	26,120	26,216
Equipment	13,069	11,902	13,899
Other long term receivables	632	609	618
<b>Total non-current assets</b>	<b>572,383</b>	<b>571,505</b>	<b>573,174</b>
<b>CURRENT ASSETS</b>			
Other receivables	3,662	20,767	3,442
Prepaid expenses and accrued income	4,347	8,231	1,919
Cash and cash equivalents	20,186	84,855	41,851
<b>Total current assets</b>	<b>28,195</b>	<b>113,853</b>	<b>47,212</b>
<b>TOTAL ASSETS</b>	<b>600,578</b>	<b>685,358</b>	<b>620,386</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<b>Shareholders' equity</b>			
Share capital	10,135	9,970	9,970
Additional paid-in capital	1,135,412	1,131,150	1,130,636
Reserves	-335	3,320	-182
Retained earnings (including profit/loss for the period)	-660,040	-544,100	-625,985
<b>Total equity attributable to the shareholders of the parent company</b>	<b>485,171</b>	<b>600,339</b>	<b>514,439</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Other long-term liabilities	850	39,268	22,845
Lease liabilities	23,792	23,918	23,706
<b>Total non-current liabilities</b>	<b>24,642</b>	<b>63,186</b>	<b>46,550</b>
<b>Current liabilities</b>			
Lease liabilities	2,616	2,259	2,413
Accounts payable	3,686	6,941	7,411
Short-term part of long-term liabilities to credit institutions	68,064	-	29,198
Other liabilities	5,777	6,858	4,765
Accrued expenses and deferred income	10,622	5,774	15,610
<b>Total current liabilities</b>	<b>90,765</b>	<b>21,832</b>	<b>59,397</b>
<b>Total liabilities</b>	<b>115,407</b>	<b>85,018</b>	<b>105,947</b>
<b>Total shareholders' equity and liabilities</b>	<b>600,578</b>	<b>685,358</b>	<b>620,386</b>

## Consolidated statement of changes in equity

Attributable to owners of Mendus AB (publ)

Amounts in KSEK	Share capital	Additional paid in capital	Reserves	Retained earnings inc. profit/loss for the period	Total
<b>Opening shareholders' equity 2023-01-01</b>	<b>9,970</b>	<b>1,130,636</b>	<b>-181</b>	<b>-625,985</b>	<b>514,440</b>
Profit/loss for the period	-	-	-	-34,055	-34,055
Other comprehensive income	-	-	-154	-	-154
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-154</b>	<b>-34,055</b>	<b>-34,209</b>
<b>Transactions with owners</b>					
Issued warrants	-	250	-	-	250
Share issue	165	4,526	-	-	4,691
Costs for new share issue	-	-	-	-	-
<b>Total transaction with owners</b>	<b>165</b>	<b>4,776</b>	<b>-</b>	<b>-</b>	<b>4,941</b>
<b>Shareholders' equity 2023-06-30</b>	<b>10,135</b>	<b>1,135,412</b>	<b>-336</b>	<b>-660,040</b>	<b>485,172</b>
<hr/>					
<b>Opening shareholders' equity 2022-01-01</b>	<b>9,970</b>	<b>1,130,334</b>	<b>3,638</b>	<b>-487,199</b>	<b>656,743</b>
Profit/loss for the period	-	-	-	-56,900	-56,900
Other comprehensive income	-	-	-318	-	-318
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-318</b>	<b>-56,900</b>	<b>-57,219</b>
<b>Transactions with owners</b>					
Issued warrants	-	815	-	-	815
Share issue	-	-	-	-	-
Costs for new share issue	-	-	-	-	-
<b>Total transaction with owners</b>	<b>-</b>	<b>815</b>	<b>-</b>	<b>-</b>	<b>815</b>
<b>Shareholders' equity 2022-06-30</b>	<b>9,970</b>	<b>1,131,149</b>	<b>3,319</b>	<b>-544,100</b>	<b>600,339</b>
<hr/>					
<b>Opening shareholders' equity 2022-01-01</b>	<b>9,970</b>	<b>1,130,334</b>	<b>3,638</b>	<b>-487,199</b>	<b>656,743</b>
Profit/loss for the period	-	-	-	-138,786	-138,786
Other comprehensive income	-	-	-3,819	-	-3,819
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-3,819</b>	<b>-138,786</b>	<b>-142,605</b>
<b>Transactions with owners</b>					
Issued warrants	-	302	-	-	302
Share issue	-	-	-	-	-
Costs for new share issue	-	-	-	-	-
<b>Total transaction with owners</b>	<b>-</b>	<b>302</b>	<b>-</b>	<b>-</b>	<b>302</b>
<b>Shareholders' equity 2022-12-31</b>	<b>9,970</b>	<b>1,130,636</b>	<b>-181</b>	<b>-625,985</b>	<b>514,440</b>



## Consolidated statement of cash flows

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
<b>OPERATING ACTIVITIES</b>					
Operating profit/loss	-27,737	-28,133	-57,346	-54,953	-133,684
Adjustment for items not included in cash flow	-3,155	1,778	-1,007	2,909	-1,542
Interest expense paid	25,302	-697	25,131	-1,121	-1,135
<b>Cash flow from operating activities before changes in working capital</b>	<b>-5,590</b>	<b>-27,052</b>	<b>-33,222</b>	<b>-53,165</b>	<b>-136,361</b>
Increase/decrease in other current receivables	-2,031	-2,095	-2,540	919	23,465
Increase/decrease in accounts payable	-131	3,131	-3,760	-4,669	-4,146
Increase/decrease in other current liabilities	438	-10,268	-1,345	-2,429	7,711
<b>Cash flow from operating activities</b>	<b>-7,313</b>	<b>-36,284</b>	<b>-40,867</b>	<b>-59,344</b>	<b>-109,331</b>
<b>INVESTMENT ACTIVITIES</b>					
Investment in tangible fixed asse	2,826	-3,633	2,334	-11,524	-12,097
Investments in long-term receivables	-10	239	-14	234	-228
<b>Cash flow from investment activities</b>	<b>2,815</b>	<b>-3,394</b>	<b>2,320</b>	<b>-11,290</b>	<b>-12,324</b>
<b>FINANCING ACTIVITIES</b>					
New Share issue	1,499	-	4,691	-	-
New share Issue costs	-	-	-	-	-
Repayment of borrowings	-3,254	-	-4,525	-	-2,731
New loans	-10,894	1,572	16,872	-33	10,925
<b>Cash flow from financing activities</b>	<b>-12,650</b>	<b>1,572</b>	<b>17,038</b>	<b>-33</b>	<b>8,194</b>
Cash and cash equivalents at the beginning of the period	37,496	122,926	41,851	155,313	155,313
Cash flow for the period	-17,147	-38,106	-21,509	-70,667	-113,461
Foreign exchange difference in cash and cash equivalents	-162	35	-155	209	-2
<b>Cash and cash equivalents at the end of the period</b>	<b>20,186</b>	<b>84,855</b>	<b>20,186</b>	<b>84,855</b>	<b>41,850</b>

FINANCIAL REPORTS  
**PARENT COMPANY**

## Parent Company income statement

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Intercompany receivables	648	866	1,514	1,732	3,674
Revenue	–	–	–	1,794	1,794
Other operating income	12	–	294	–	272
<b>Total revenue</b>	<b>660</b>	<b>866</b>	<b>1,808</b>	<b>3,526</b>	<b>5,740</b>
<b>OPERATING EXPENSES</b>					
Administration expenses	-3,485	-10,300	-11,693	-18,286	-43,814
Research and development expenses	-7,085	-5,125	-10,218	-12,164	-24,963
Other operating expenses	-24	-252	-195	-913	-1,116
<b>Operating profit/loss</b>	<b>-9,933</b>	<b>-14,812</b>	<b>-20,298</b>	<b>-27,837</b>	<b>-64,153</b>
<b>RESULT FROM FINANCIAL ITEMS</b>					
Financial income	–	35	–	209	163
Financial costs	-1,080	-18	-1,324	-14	-657
<b>Profit/loss after financial items</b>	<b>-11,013</b>	<b>-14,795</b>	<b>-21,622</b>	<b>-27,642</b>	<b>-64,647</b>
<b>TOTAL PROFIT/LOSS BEFORE TAXES</b>	<b>-11,013</b>	<b>-14,795</b>	<b>-21,622</b>	<b>-27,642</b>	<b>-64,647</b>
Income tax	–	–	–	–	–
<b>PROFIT/LOSS FOR THE PERIOD</b>	<b>-11,013</b>	<b>-14,795</b>	<b>-21,622</b>	<b>-27,642</b>	<b>-64,647</b>
Earnings/loss per share before and after dilution (SEK), for profit attributable to owner of the parent company's shareholders.	-0.06	-0.07	-0.11	-0.14	-0.32

## Parent Company statement of comprehensive income

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Result for the period	-11,013	-14,795	-21,622	-27,642	-64,647
Other comprehensive income	–	–	–	–	–
<b>Total comprehensive income for the period</b>	<b>-11,013</b>	<b>-14,795</b>	<b>-21,622</b>	<b>-27,642</b>	<b>-64,647</b>

Profit/loss for the period and total comprehensive income, are in their entirety attributable to the parent company's shareholders.

## Parent Company balance sheet

Amounts in KSEK	2023-06-30	2022-06-30	2022-12-31
<b>ASSETS</b>			
<b>Tangible assets</b>			
Participants in Group companies	746,581	692,231	711,422
Other long term receivables	394	394	394
<b>Total financial assets</b>	<b>746,975</b>	<b>692,625</b>	<b>711,816</b>
<b>Total fixed assets</b>	<b>746,975</b>	<b>692,625</b>	<b>711,816</b>
<b>CURRENT ASSETS</b>			
Tax credits and related receivables	1,514	–	1,076
Other receivables	1,438	837	1,480
Prepaid expenses and accrued income	3,050	6,844	854
<b>Total current receivable</b>	<b>6,002</b>	<b>7,681</b>	<b>3,410</b>
Cash and bank balances	18,667	73,619	27,840
<b>Total current assets</b>	<b>24,669</b>	<b>81,301</b>	<b>31,250</b>
<b>TOTAL ASSETS</b>	<b>771,645</b>	<b>773,926</b>	<b>743,066</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<b>Restricted equity</b>			
Share capital	10,135	9,970	9,970
<b>Total restricted equity</b>	<b>10,135</b>	<b>9,970</b>	<b>9,970</b>
<b>Unrestricted equity</b>			
Share premium reserve	1,420,601	1,416,339	1,415,825
Retained earnings	-703,964	-652,163	-639,316
Profit/loss for the period	-21,622	-14,795	-64,647
<b>Total unrestricted equity</b>	<b>695,015</b>	<b>749,381</b>	<b>711,862</b>
<b>Total shareholders' equity</b>	<b>705,150</b>	<b>759,351</b>	<b>721,832</b>
<b>LIABILITIES</b>			
<b>LONG-TERM LIABILITIES</b>			
Other long-term liabilities	850	850	10,957
<b>Total long-term liabilities</b>	<b>850</b>	<b>850</b>	<b>10,957</b>
<b>CURRENT LIABILITIES</b>			
Accounts payable	–	2,334	773
Intercompany liabilities	11,117	–	1,844
Other liabilities	50,495	2,414	663
Accrued expenses and deferred income	4,033	8,975	6,997
<b>Total current liabilities</b>	<b>65,645</b>	<b>13,724</b>	<b>10,277</b>
<b>Total liabilities</b>	<b>66,495</b>	<b>14,574</b>	<b>21,234</b>
<b>Total shareholders' equity and liabilities</b>	<b>771,645</b>	<b>773,926</b>	<b>743,066</b>



## Parent Company statement of changes in equity

Amounts in KSEK	Share capital	Share premium reserve	Retained earnings inc. profit/loss for the period	Total
<b>Opening shareholders' equity 2023-01-01</b>	<b>9,970</b>	<b>1,415,825</b>	<b>-703,963</b>	<b>721,832</b>
Profit/loss for the period	-	-	-21,622	-21,622
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-21,622</b>	<b>-21,622</b>
<b>Transactions with owners</b>				
Issued warrants	-	250	-	250
Share issue	165	4,526	-	4,691
Costs for new share issue	-	-	-	-
<b>Total transaction with owners</b>	<b>165</b>	<b>4,776</b>	<b>-</b>	<b>4,941</b>
<b>Shareholders' equity 2023-06-30</b>	<b>10,135</b>	<b>1,420,601</b>	<b>-725,585</b>	<b>705,151</b>
<hr/>				
<b>Opening shareholders' equity 2022-01-01</b>	<b>9,970</b>	<b>1,415,523</b>	<b>-639,316</b>	<b>786,177</b>
Profit/loss for the period	-	-	-27,642	-27,642
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-27,642</b>	<b>-27,642</b>
<b>Transactions with owners</b>				
Issued warrants	-	816	-	816
Share issue	-	-	-	-
Costs for new share issue	-	-	-	-
<b>Total transaction with owners</b>	<b>-</b>	<b>816</b>	<b>-</b>	<b>816</b>
<b>Shareholders' equity 2022-06-30</b>	<b>9,970</b>	<b>1,415,931</b>	<b>-666,958</b>	<b>759,351</b>
<hr/>				
<b>Opening shareholders' equity 2022-01-01</b>	<b>9,970</b>	<b>1,415,523</b>	<b>-639,316</b>	<b>786,177</b>
Profit/loss for the period	-	-	-64,647	-64,647
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-64,647</b>	<b>-64,647</b>
<b>Transactions with owners</b>				
Issued warrants	-	302	-	302
Share issue	-	-	-	-
Costs for new share issue	-	-	-	-
<b>Total transaction with owners</b>	<b>-</b>	<b>302</b>	<b>-</b>	<b>302</b>
<b>Shareholders' equity 2022-12-31</b>	<b>9,970</b>	<b>1,415,825</b>	<b>-703,963</b>	<b>721,832</b>

## Parent Company cash flow statement

Amounts in KSEK	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
<b>Operating activities</b>					
Operating profit/loss before financial items	-11,013	-14,812	-21,622	-27,837	-64,153
Adjustment for items not included in cash flow	106	408	250	816	302
Interest expense paid	-1,080	-18	-1,324	-14	-494
<b>Cash flow from operating activities before changes in working capital</b>	<b>-11,987</b>	<b>-14,422</b>	<b>-22,696</b>	<b>-27,035</b>	<b>-64,345</b>
Increase/decrease in accounts receivable	-604	-	-915	-10,617	3,207
Increase/decrease in other current receivables	-2,487	-471	-1,677	2,710	3,776
Increase/decrease in accounts payable	8,050	1,868	8,500	-115	-9,585
Increase/decrease in other current liabilities	8,210	-3,037	6,867	-5,055	968
<b>Cash flow from operating activities</b>	<b>1,181</b>	<b>-16,062</b>	<b>-9,920</b>	<b>-40,112</b>	<b>-65,979</b>
<b>Investment activities</b>					
Increase/decrease in long term receivable	-15,425	-21,155	-10,107	-	-
Investment in financial assets	-15,024	-	-35,160	-31,635	-61,442
<b>Cash flow from investment activities</b>	<b>-30,449</b>	<b>-21,155</b>	<b>-45,266</b>	<b>-31,635</b>	<b>-61,442</b>
<b>Financing activities</b>					
New share issues	1,500	-	4,691	-	-
New loans	15,000	-	40,000	-	10,107
<b>Cash flow from financing activities</b>	<b>16,500</b>	<b>-</b>	<b>44,691</b>	<b>-</b>	<b>10,107</b>
Cash and cash equivalents at the beginning of the period	30,357	110,800	27,840	145,156	145,156
Cash flow for the period	-12,768	-37,216	-10,495	-71,746	-117,314
Foreign exchange difference in cash and cash equivalents	1,078	35	1,322	209	-2
<b>Cash and cash equivalents at the end of the period</b>	<b>18,667</b>	<b>73,619</b>	<b>18,667</b>	<b>73,619</b>	<b>27,840</b>

# Notes

## Note 1 – General information

This report covers the Swedish company Mendus AB (publ) (hereinafter "Mendus"), Swedish corporate identity no. 556629-1786. The Company is a Swedish public limited company registered in Stockholm. The address of the Company's head office is Västra Trädgårdsgatan 15, 111 53 Stockholm. The quarterly report was authorized for issue by the Board of Directors on August 28, 2023.

## Note 2 – Accounting policies

The consolidated accounts for Mendus have been prepared in accordance with the Swedish Annual Accounts Act, RFR 1 Supplementary Accounting Rules for Groups and International Financial Reporting Standards (IFRS) and interpretations from the IFRS Interpretations Committee (IFRS IC) as adopted by the EU. The consolidated financial statements have been prepared using the cost method.

The interim report has been prepared in accordance with IAS 34 Interim Reporting and the Annual Accounts Act.

The Parent Company's interim report has been prepared in accordance with the Annual Accounts Act and the Financial Reporting Council's recommendation RFR 2.

The Group's accounting principles remain unchanged and are set out in the Annual Report for 2022 (Note 2, pages 34-38).

In cases where the Parent Company applies accounting principles other than the Group's accounting principles, these are stated in the Annual Report 2022 (Note 2, page 49).

## Note 3 – Significant estimates and judgements for accounting purposes

The preparation of financial statements requires the use of accounting estimates, which will rarely correspond to the actual result. Management also makes assessments when applying the Group's accounting policies. These assessments are unchanged and are presented in the Annual Report for 2022 (note 5, page 39).

## Note 4 – Prospects, significant risks and uncertainty factors

Mendus is a research and development company. The company has not generated any significant revenue historically and is not expected to do so in the short term. The Company's product candidates are dependent on research

and development and may be delayed and/or incur higher costs. The Company is dependent on its ability to enter into licensing agreements and joint cooperation agreements, as well as reliance on a wide range of approval and compensation schemes and related laws, regulations, decisions and practices (as may be subject to change). In addition, the Company is dependent on intellectual property rights. The risk that is considered to be of particular importance for Mendus' future development is access to sufficient financial resources to support the Company's financing needs.

This report contains forward-looking statements. Actual outcomes may deviate from what has been stated. Internal factors such as successful management of research projects and intellectual property rights can affect future results. There are also external conditions, such as the economic climate, political changes and competing research projects that can affect Mendus' results.

## Crisis in Ukraine

Mendus has no direct exposure to Ukraine or Russia in its day-to-day operations and ongoing clinical trials.

For a more detailed description of significant risk factors, please refer to the Annual Report for 2022 which is available on the Company's website [www.mendus.com](http://www.mendus.com).

## Note 5 – Information on transactions with closely related parties

The parent company Mendus AB is related to the subsidiary Mendus BV. During the second quarter, purchases in Mendus AB of goods and services relate to KSEK -6,408 (-4,302) and sales to KSEK 648 (866). For the year so far, purchases in Mendus AB of goods and services refer to KSEK -11,117 (-8,510) and sales refer to KSEK 1,514 (1,732). Mendus AB has an outstanding long-term debt to Van Herk Investments B.V. of KSEK 50,992. During the quarter, interest was paid in the amount of KSEK 992. No further transactions were made with related parties during the year. Transactions with related parties are conducted on market terms.

## Note 6 – Financial instruments

Mendus financial assets and liabilities consist of cash and cash equivalents, other current receivables, other long-term receivables, other long-term securities holdings, other long-term liabilities, other current liabilities and accounts payables. The fair value of all financial instruments is substantially consistent with their carrying amounts.



#### **Note 7 – Significant events after end of period**

- » At the Extraordinary General Meeting in Mendus AB on July 10, 2023, in accordance with the Board of Directors' proposal, resolved to amend the Articles of Association with regard to the Company's limits for share capital and the number of shares. The prospectus for the Rights Issue and the Directed Issue were approved and registered by the Swedish Financial Supervisory Authority and published on the Company's website.
- » On July 28, 2023, it is announced on the Company's website that the outcome of the Rights Issue shows that 43,528,426 units, corresponding to approximately 64.4 percent of the Rights Issue, were subscribed for with the support of unit rights. In addition, 2,696,986 units were subscribed for without unit rights, of which 2,696,986 units, corresponding to approximately 4.0 percent of the Rights Issue, have been allocated to investors who have subscribed without the support of unit rights. Accordingly, guarantee commitments of 21,339,425 units, corresponding to approximately 31.6 percent of the offered units, will be utilized. In total, Mendus will receive approximately SEK 317 million before set-off and transaction costs through the Rights Issue and the Directed Issue.

Through the Rights Issue, Mendus' share capital will increase by SEK 23,647,692.95, from SEK 10,134,725.60 to SEK 33,782,418.55 and the number of shares in Mendus will increase by 472,953,859 shares, from 202,694,512 shares to 675,648,371 shares. Through the Directed Issue, the number of shares will increase by 187,500,000 and the share capital will increase by SEK 9,375,000.00.

Upon full exercise of warrants of series TO3 (the "Options") from the Rights Issue and the Directed Issue, which expires on March 29, 2024, the Company will receive additional proceeds of up to approximately MSEK 90.6. The subscription price upon exercise of the Options is SEK 0.48, i.e. the same as the subscription price in the Transaction.

#### **Note 8 – Participations in Group companies**

Shares in Group companies refer to shares in Mendus B.V, which were acquired on 21 December 2020. Mendus holds 100% of the capital and voting rights. The number of shares amounts to 60,000,000 shares.



## Key performance measurements

The Company presents in this report certain key performance measures, including two measures that is not defined under IFRS, namely expenses relating to research and development/operating expenses and equity ratio. These financial performance measures should not be viewed in isolation or be considered to replace the performance indicators that have been prepared in accordance with IFRS. In

addition, such performance measure as the Company has defined it should not be compared with other performance measures with similar names used by other companies.

This is because the above-mentioned performance measure is not always defined in the same manner, and other companies may calculate them differently to Mendus.

## The Group

	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Share capital at end of period, KSEK	10,135	9,970	10,135	9,970	9,970
Equity at the end of period, KSEK	485,171	600,339	485,171	600,339	514,439
Earnings per share before and after dilution, SEK	-0.02	-0.15	-0.17	-0.29	-0.70
Research and development costs, KSEK	-19,221	-18,687	-39,003	-37,502	-87,049
Research and development costs/operating expenses, %	69%	66%	68%	66%	64%

## Parent Company

	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Total registered shares at the beginning of period	201,311,406	199,400,599	199,400,599	199,400,599	199,400,599
Total registered shares at the end of period	202,694,512	199,400,599	202,694,512	199,400,599	199,400,599
Share capital at end of period, KSEK	10,135	9,970	10,135	9,970	9,970
Equity at the end of period, KSEK	705,151	759,351	705,151	759,351	721,832
Earnings per share before and after dilution, SEK	3.48	3.81	3.48	3.81	3.62
Research and development costs, KSEK	-7,085	-5,125	-10,218	-12,164	-24,963
Research and development costs/operating expenses, %	67%	33%	46%	39%	36%

## Definitions and reconciliation of alternative performance measurements

Alternative performance measurements	Definition	Justification
Equity ratio	Total shareholders' equity divided by total assets	The key ratio provides useful information of the Company's capital structure.
Research & development costs/operating expenses, %	Research & development costs/operating expenses, %	The research and development /operating expenses ratio is an important complement because it allows for a better evaluation of the Company's economic trends and the proportion of its costs that are attributable to the Company's core business.

## Derivation The Group

	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Total shareholders equity at the end of the period, KSEK	485,171	600,339	485,171	600,339	514,439
Total assets at the end of the period, KSEK	600,578	685,358	600,578	685,358	620,387
Equity ratio at the end of the period, %	81%	88%	81%	88%	83%
Research & development costs	-19,221	-18,687	-39,003	-37,502	-87,049
Administrative costs	-8,438	-9,226	-18,352	-18,480	-48,876
Other operating expenses	-91	-256	-290	-917	-1,134
Total operating expenses	-27,750	-28,169	-57,645	-56,899	-137,060
Research & development costs/operating expenses, %	69%	66%	68%	66%	64%

## Derivation Parent Company

	2023 apr-jun	2022 apr-jun	2023 jan-jun	2022 jan-jun	2022 jan-dec
Total shareholders equity at the end of the period, KSEK	705,151	759,351	705,151	759,351	721,832
Total assets at the end of the period, KSEK	771,645	773,926	771,645	773,926	743,066
Equity ratio at the end of the period, %	91%	98%	91%	98%	97%
Research & development costs	-7,085	-5,125	-10,218	-12,164	-24,963
Administrative costs	-3,485	-10,300	-11,693	-18,286	-43,814
Other operating expenses	-24	-252	-195	-913	-1,116
Total operating expenses	-10,594	-15,667	-22,106	-31,363	-69,893
Research & development costs/operating expenses, %	67%	33%	46%	39%	36%

## Financial Calendar

- Publication of Q3 Report 9 November 2023
- Publication of Year-end Report 2023 14 February 2024

### For further information, please contact:

#### **Erik Manting, CEO, Mendus**

Phone: +46 (0)8 732 8400

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

#### **Lotta Ferm, CFO, Mendus**

Telephone: +46 (0)8 732 8400

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

Postal address: Västra Trädgårdsgatan 15

SE- 111 53 Stockholm, Sweden

Corporate identity number: 556629-1786

The information contained in this report is that which Mendus (publ), is obliged to publish in accordance with the Swedish Securities Market Act (SFS 2007:528).

The information was submitted for publication, through the agency of the contact persons set out above, on August 29, 2023, at 08:00 a.m. CET.

The Group is referred to unless otherwise stated in this Year-end report. Figures in parentheses refer to the corresponding period last year.

This report has been prepared in a Swedish original version and translated into English. In the event of any inconsistency between the two versions, the Swedish language version should have precedence.



[www.mendus.com](http://www.mendus.com)



Head Office  
Västra Trädgårdsgatan 15  
111 53 Stockholm  
Sweden



R&D Offices  
Emmy Noetherweg 2K  
2333 BK Leiden  
The Netherlands



Changing the course of cancer treatment

